^
    Apply
    INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (NCT04295759)
    Phase 1
    Pediatric Brain Tumor Consortium
    Completed
    Last update posted :
    02/19/2025
    Initiation :
    07/27/2020
    Primary completion :
    12/31/2023
    Completion :
    12/01/2024
    HER-2 • CD4 • ADAM10
    |
    aderbasib (INCB7839)
    A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma (NCT05943795)
    Phase 3
    Sichuan Baili Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/14/2023
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK
    |
    KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion
    |
    docetaxel • izalontamab (SI-B001)
    Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor (NCT04100694)
    Phase N/A
    Merus N.V.
    Available
    Last update posted :
    02/05/2025
    NRG1
    |
    NRG1 fusion
    |
    Bizengri (zenocutuzumab-zbco)
    Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers (NCT05588609)
    Phase 2
    Merus N.V.
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    11/17/2022
    Primary completion :
    10/01/2025
    Completion :
    03/01/2026
    NRG1
    |
    NRG1 fusion
    |
    Gilotrif (afatinib) • Xtandi (enzalutamide) • abiraterone acetate • Bizengri (zenocutuzumab-zbco)
    A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) (NCT02912949)
    Phase 2
    Merus N.V.
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    01/01/2015
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    NRG1
    |
    NRG1 fusion
    |
    Bizengri (zenocutuzumab-zbco)
    Clinical Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (NCT05668858)
    Phase 1/2
    Sichuan Baili Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    04/04/2024
    Initiation :
    02/10/2023
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    PD-L1
    |
    carboplatin • izalontamab (SI-B001) • danvilostomig (SI-B003)
    SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. (NCT05020457)
    Phase 2
    Sichuan Baili Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    01/31/2024
    Initiation :
    12/07/2021
    Primary completion :
    04/01/2024
    Completion :
    04/01/2024
    EGFR • ALK
    |
    EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type
    |
    cisplatin • Tagrisso (osimertinib) • paclitaxel • docetaxel • pemetrexed • izalontamab (SI-B001)
    A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors. (NCT05203601)
    Phase 1
    Shanghai Institute Of Biological Products
    Completed
    Last update posted :
    12/27/2023
    Initiation :
    11/26/2020
    Primary completion :
    12/06/2022
    Completion :
    12/06/2022
    EGFR • HER-2 • TP53 • PIK3CA • ERBB3 • NOTCH1 • NRG1 • NOTCH2 • FAT1 • NOTCH4
    |
    HER-2 overexpression
    |
    docetaxel
    A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT05949606)
    Phase 1/2
    Sichuan Baili Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    11/29/2023
    Initiation :
    10/30/2023
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK
    |
    BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion
    |
    izalontamab (SI-B001) • danvilostomig (SI-B003)
    Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors (CRESTONE) (NCT04383210)
    Phase 2
    Elevation Oncology
    Active, not recruiting
    Last update posted :
    08/08/2023
    Initiation :
    09/29/2020
    Primary completion :
    01/01/2025
    Completion :
    03/01/2025
    NRG1
    |
    NRG1 fusion
    |
    seribantumab (MM-121)
    Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer (NCT02167854)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    07/09/2021
    Initiation :
    06/16/2014
    Primary completion :
    07/07/2021
    Completion :
    07/07/2021
    HER-2 • PIK3CA
    |
    HER-2 amplification • PIK3CA mutation
    |
    Herceptin (trastuzumab) • Piqray (alpelisib) • elgemtumab (LJM-716)
    Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer (NCT01211483)
    Phase 1b/2
    Daiichi Sankyo, Inc.
    Completed
    Last update posted :
    06/16/2021
    Initiation :
    09/01/2010
    Primary completion :
    10/01/2013
    Completion :
    11/23/2013
    KEAP1 • NRG1
    |
    erlotinib • patritumab (U3-1287)
    A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer (NCT01598077)
    Phase 1
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    12/19/2020
    Initiation :
    07/01/2012
    Primary completion :
    03/01/2014
    Completion :
    03/01/2014
    HER-2
    |
    elgemtumab (LJM-716)
    A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors (NCT01911936)
    Phase 1
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    12/17/2020
    Initiation :
    09/01/2013
    Primary completion :
    03/01/2015
    Completion :
    03/01/2015
    HER-2
    |
    HER-2 overexpression
    |
    elgemtumab (LJM-716)
    A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients (NCT02473731)
    Phase 1
    Celldex Therapeutics
    Completed
    Last update posted :
    08/01/2019
    Initiation :
    10/01/2015
    Primary completion :
    09/22/2016
    Completion :
    10/10/2016
    ERBB3
    |
    CDX-3379
    Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors (NCT01966445)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    07/01/2019
    Initiation :
    11/26/2013
    Primary completion :
    09/18/2017
    Completion :
    09/18/2017
    ERBB3 • CA 19-9
    |
    GSK2849330
    Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors (NCT02345174)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    02/21/2019
    Initiation :
    03/19/2015
    Primary completion :
    06/02/2016
    Completion :
    06/02/2016
    ERBB3
    |
    ERBB3 expression
    |
    GSK2849330
    A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer (CARRIE) (NCT02399137)
    Phase 2
    Merrimack Pharmaceuticals
    Completed
    Last update posted :
    09/18/2018
    Initiation :
    05/01/2015
    Primary completion :
    08/01/2018
    Completion :
    08/01/2018
    IGF1
    |
    gemcitabine • albumin-bound paclitaxel • istiratumab (MM-141)
    Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors (NCT00820560)
    Phase 1
    Incyte Corporation
    Completed
    Last update posted :
    01/17/2018
    Initiation :
    01/01/2005
    Primary completion :
    01/01/2009
    Completion :
    01/01/2009
    HER-2
    |
    aderbasib (INCB7839)
    A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (NCT01918254)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    09/12/2017
    Initiation :
    08/06/2013
    Primary completion :
    10/07/2016
    Completion :
    10/07/2016
    HER-2 • ERBB3
    |
    HER-2 expression
    |
    paclitaxel • Perjeta (pertuzumab) • lumretuzumab (RG7116)
    A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors (NCT02014909)
    Phase 1
    Celldex Therapeutics
    Completed
    Last update posted :
    07/24/2017
    Initiation :
    01/01/2014
    Primary completion :
    05/25/2017
    Completion :
    06/05/2017
    EGFR • HER-2 • KRAS • BRAF
    |
    HER-2 positive • BRAF V600E • BRAF V600 • EGFR expression • EGFR wild-type • RAS wild-type
    |
    CDX-3379
    A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (NCT01482377)
    Phase 1a/1b
    Hoffmann-La Roche
    Completed
    Last update posted :
    01/27/2017
    Initiation :
    12/01/2011
    Primary completion :
    02/01/2016
    Completion :
    02/01/2016
    EGFR • ERBB3
    |
    EGFR expression • ERBB3 expression • EGFR positive
    |
    Erbitux (cetuximab) • erlotinib • lumretuzumab (RG7116)
    Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) (NCT01652482)
    Phase 2
    Genentech, Inc.
    Completed
    Last update posted :
    11/02/2016
    Initiation :
    10/01/2012
    Primary completion :
    11/01/2014
    Completion :
    11/01/2014
    KRAS
    |
    KRAS wild-type • RAS wild-type
    |
    Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium • duligotuzumab (MEHD7945A)
    A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers (NCT01209195)
    Phase 1
    Merrimack Pharmaceuticals
    Completed
    Last update posted :
    09/08/2016
    Initiation :
    10/01/2010
    Primary completion :
    05/01/2014
    Completion :
    07/01/2014
    HER-2
    |
    HER-2 overexpression
    |
    paclitaxel • seribantumab (MM-121)
    Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment (NCT00734305)
    Phase 1
    Merrimack Pharmaceuticals
    Completed
    Last update posted :
    09/01/2016
    Initiation :
    07/01/2008
    Primary completion :
    05/01/2010
    Completion :
    09/01/2013
    HER-2 • PGR
    |
    seribantumab (MM-121)
    A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS (NCT01986166)
    Phase 1
    Genentech, Inc.
    Completed
    Last update posted :
    07/18/2016
    Initiation :
    11/01/2013
    Primary completion :
    01/01/2016
    Completion :
    01/01/2016
    KRAS
    |
    KRAS mutation
    |
    Cotellic (cobimetinib) • duligotuzumab (MEHD7945A)
    Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer (NCT01151046)
    Phase 2
    Merrimack Pharmaceuticals
    Completed
    Last update posted :
    05/12/2016
    Initiation :
    06/01/2010
    Primary completion :
    06/01/2014
    Completion :
    09/01/2014
    HER-2
    |
    HER-2 negative
    |
    exemestane • seribantumab (MM-121)
    A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer (NCT01421472)
    Phase 2
    Merrimack Pharmaceuticals
    Completed
    Last update posted :
    05/03/2016
    Initiation :
    08/01/2011
    Primary completion :
    12/01/2013
    Completion :
    06/01/2014
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    paclitaxel • doxorubicin hydrochloride • cyclophosphamide • seribantumab (MM-121)
    Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) (THYME) (NCT00900627)
    Phase 2
    AstraZeneca
    Completed
    Last update posted :
    01/20/2016
    Initiation :
    06/01/2009
    Primary completion :
    04/01/2012
    Completion :
    02/01/2015
    HER-2
    |
    HER-2 expression
    |
    paclitaxel • sapitinib (AZD8931)
    A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer (NCT01304784)
    Phase 1
    Merrimack Pharmaceuticals
    Completed
    Last update posted :
    12/16/2015
    Initiation :
    01/01/2011
    Primary completion :
    04/01/2014
    Completion :
    06/01/2014
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • cisplatin • paclitaxel • docetaxel • lapatinib • capecitabine • MM 111